Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Molybdenum-99 (Mo-99) is a radioisotope used as the parent isotope in technetium-99m (99mTc) generators. It decays via beta emission to 99mTc, a metastable nuclear isomer of technetium widely used in nuclear medicine. The Mo-99 is adsorbed onto an alumina column in the generator, and as it decays, the resulting 99mTc (as pertechnetate) is eluted with saline, providing a readily available source of the radiotracer for diagnostic imaging. While Mo-99 itself isn't directly a therapeutic target, its role as a precursor to 99mTc makes it crucial for a wide range of diagnostic procedures.
Serves as the parent isotope in a technetium generator, decaying to produce technetium-99m, which is then used as a radiotracer for diagnostic imaging. The mechanism of action is based on the gamma emission of technetium-99m, which is detected by gamma cameras to visualize organ function and structure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Molybdenum-99 (Mo-99).